Impact of relative dose intensity of trabectedin with pegfilgrastim support: a single-centre retrospective study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact of relative dose intensity of trabectedin with pegfilgrastim support: a single-centre retrospective study

Published:2023-01-12 Issue:8 Volume:35 Page:737-744
ISSN:1120-009X
Container-title:Journal of Chemotherapy
language:en
Short-container-title:Journal of Chemotherapy

Author:

Saito Yoshimasa¹²^ORCID,Shimoi Tatsunori³,Iwata Shintaro⁴,Maejima Aiko⁵,Abe Kentaro²,Udagawa Ryoko²,Yonemori Kan³,Furukawa Tetsuya²,Wakao Fumihiko⁶

Affiliation:

1. Division of Quality Assurance Programs, Institute for Cancer Control, National Cancer Center, Tokyo, Japan

2. Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan

3. Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

4. Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital, Tokyo, Japan

5. Department of Urology, National Cancer Center Hospital, Tokyo, Japan

6. Institute for Cancer Control, National Cancer Center, Tokyo, Japan

Publisher

Informa UK Limited

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/1120009X.2022.2164116

Reference31 articles.

1. First-Line Therapy for Metastatic Soft Tissue Sarcoma

2. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

3. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

4. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

5. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3